Cancer and the constitution - Choice at life's end

New England Journal of Medicine

Volumn 357, Issue 4, 2007, Pages 408-413

  Annas, George J ^a  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER MORTALITY; CANCER PATIENT; CANCER RESEARCH; CLINICAL DECISION MAKING; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMED CONSENT; LAW; PATIENT RIGHT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TERMINAL DISEASE; UNITED STATES;

EID: 34547156660     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMhle070625     Document Type: Article

References (32)

1. Coetzee JM. Age of iron. London: Seeker & Warburg, 1990.
2. Patterson JT. The dread disease: cancer and modern American culture. Cambridge, MA: Harvard University Press, 1987.
3. Abigail Alliance v. Von Eschenbach, 445 F.3d 470 (DC Cir 2006). Vacated 469 F.3d 129 (DC Cir 2006).
4. Proposed rules for charging for investigational drugs and expanded access to investigational drugs for treatment use. Rockville, MD: Food and Drug Administration, 2006. (Accessed July 6, 2007, at http://www.fda.gov/cder/ regulatory/applications/IND_PR.htm.)
5. Abigail Alliance v. Von Eschenbach, 429 F.3d 129 (DC Cir 2006).
6. Jacobson PD, Parmet WE. A new era of unapproved drugs: the case of Abigail Alliance v Von Eschenbach. JAMA 2007;297:205-8.
7. Cruzan v. Director, Missouri Dept. of Health, 497 U.S. 261 (1990).
8. United States v. Rutherford, 442 U.S. 544 (1979).
9. Washington v. Glucksberg, 521 U.S. 702 (1997).
10. Vacco v. Quill, 521 U.S. 793 (1997).
11. Annas GJ. The bell tolls for a constitutional right to assisted suicide. N Engl J Med 1997;337:1098-103.
12. Gonzales v. Oregon, 546 U.S. 243 (2006).
13. Annas GJ. "I want to live": medicine betrayed by ideology in the political debate over Terri Schiavo. Stetson Law Rev 2005;35:49-80.
14. How about a "Kianna's Law"? Wall Street Journal. March 24, 2005:A14.
15. Kianna's legacy. Wall Street Journal. March 29, 2005:Al4.
16. Groopman J. The right to a trial: should dying patients have access to experimental drugs? The New Yorker. December 18, 2006:40-7.
17. ACCESS Act (Access, Compassion, Care, and Ethics for Seriously Ill Patients), S. 1956, 109th Cong (2005).
18. Annas GJ. Faith (healing), hope and charity at the FDA: the politics of AIDS drug trials. Villanova Law Rev 1989;34:771-97.
19. FDA proposes rules overhaul to expand availability of experimental drugs: the agency also clarifies permissible charges to patients. Rockville, MD: Food and Drug Administration, December 11, 2006. (Accessed July 6, 2007, at http://www.fda.gov/bbs/topics/NEWS/2006/NEW01520.html.)
20. Prud'homme A. The cell game: Sam Waksal's fast money and false promises - and the fate of ImClone's cancer drug. New York: Harper Business, 2004.
21. Katz J. The silent world of doctor and patient. New Haven, CT: Yale University Press, 1984:151.
22. Anand G. Saying no to Penelope: father seeks experimental cancer drug, but a biotech firm says risk is too high. Wall Street Journal. May 1, 2007:A1.
23. Robertson J. Controversial medical treatment and the right to health care. Hastings Cent Rep 2006;36:15-20.
24. Culbert ML. Vitamin B17: Forbidden weapon against cancer. New Rochelle, NY: Arlington House, 1974.
25. Miller HI. Paternalism costs lives. Wall Street Journal. March 2, 2006:A15.
26. Annas GJ. The changing landscape of human experimentation: Nuremberg, Helsinki, and beyond. Health Matrix J Law Med 1992;2:119-40.
27. Appelbaum PS, Lidz CW. Re-evaluating the therapeutic misconception: response to Miller and Joffe. Kennedy Inst Ethics J 2006;16:367-73.
28. Nathan D. The cancer treatment revolution: how smart drugs and other therapies are renewing our hope and changing the face of medicine. New York: John Wiley, 2007.
29. Brugarolas J. Renal-cell carcinoma - molecular pathways and therapies. N Engl J Med 2007;356:185-6.
30. Callahan D. False hopes: why America's quest for perfect health is a recipe for failure. New York: Simon and Schuster, 1998.
31. Berenson A. Hope, at $4,200 a dose: why a cancer drug's cost doesn't hurt demand. New York Times. October 1, 2006:BU1.
32. Anand G. From Wall Street, a warning about cancer drug prices. Wall Street Journal. March 15, 2007:A1.